| Clinical data | |
|---|---|
| Other names | CDB-4124; Proellex; Progenta; 17β-(Acetyloxy)-11β-[4-(dimethylamino)phenyl]-17α-(2-methoxyacetyl)estra-4,9-dien-3-one |
| Drug class | Selective progesterone receptor modulator |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| PubChem SID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C31H39NO5 |
| Molar mass | 505.655 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Telapristone (INNTooltip International Nonproprietary Name), astelapristone acetate (proposed brand namesProellex,Progenta; former code nameCDB-4124), is asynthetic,steroidalselective progesterone receptor modulator (SPRM) related tomifepristone which is under development by Repros Therapeutics for the treatment ofbreast cancer,endometriosis, anduterine fibroids.[1][2] It was originally developed by theNational Institutes of Health (NIH), and, as of 2017, is inphase IIclinical trials for the aforementioned indications.[1] In addition to its activity as an SPRM, the drug also has someantiglucocorticoid activity.[3]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |